Carnegie Investment Counsel Has $1.27 Million Holdings in Pfizer Inc. (NYSE:PFE)

Carnegie Investment Counsel trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 53.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,769 shares of the biopharmaceutical company's stock after selling 55,877 shares during the period. Carnegie Investment Counsel's holdings in Pfizer were worth $1,267,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Gladius Capital Management LP lifted its position in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP acquired a new stake in shares of Pfizer in the second quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Pfizer during the third quarter worth about $35,000. Joseph Group Capital Management grew its stake in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 771 shares in the last quarter. Finally, Kennebec Savings Bank acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $50,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on PFE. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective for the company. Citigroup initiated coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 price target for the company. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target for the company. Finally, Evercore ISI raised Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $32.00.

Pfizer Stock Performance

PFE stock traded down $0.19 during trading hours on Friday, hitting $26.30. 35,146,711 shares of the stock were exchanged, compared to its average volume of 35,869,448. The company has a 50-day simple moving average of $26.08 and a two-hundred day simple moving average of $27.99. The firm has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. During the same quarter in the previous year, the company earned ($0.17) EPS. The business's revenue was up 31.2% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio (DPR) is 232.43%.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company's stock, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.